Symbols / SILO Stock $0.50 +5.57% Silo Pharma, Inc.

Healthcare • Biotechnology • United States • NCM
SILO (Stock) Chart
O: — H: — L: — C: — V: —
SMA 20: SMA 50: SMA 200:
Stock Fundamentals
Scroll to Statements
Index EQUITY
Sector Healthcare
Industry Biotechnology
CEO Mr. Eric Weisblum
Exch · Country NCM · United States
Market Cap 8.13M
Enterprise Value 224.53K
Income -4.23M
Sales 72.10K
FCF (ttm) -3.56M
Book/sh 0.47
Cash/sh 0.48
Employees 3
Insider 10d
IPO Jan 08, 2021
Div forward ($/yr)
Div TTM ($/yr)
Dividend Yield
Ex-Div Date
5Y Avg Yield
Yield vs 5Y Avg
Payout 0.00%
P/E
Forward P/E -0.71
PEG
P/S 112.80
P/B 1.06
P/C
EV/EBITDA -0.05
EV/Sales 3.11
Quick Ratio 10.55
Current Ratio 11.36
Debt/Eq
LT Debt/Eq
EPS (ttm) -0.50
EPS next Y -0.70
EPS Growth
Revenue Growth 0.00%
EPS Gr Q/Q
Rev Gr Q/Q
Earnings (next) 2024-03-25
Earnings (prior) 2024-03-25
ROA -35.63%
ROE -74.57%
ROIC
Gross Margin 38.57%
Oper. Margin -43.63%
Profit Margin 0.00%
Shs Outstand 16.27M
Shs Float 13.79M
Insider Own 6.00%
Instit Own 7.46%
Short Float 3.34%
Short Ratio 0.06
Short Interest 522.54K
52W High 1.15
vs 52W High -56.52%
52W Low 0.22
vs 52W Low 126.24%
Beta 0.59
Impl. Vol.
Rel Volume 0.29
Avg Volume 4.88M
Volume 1.42M
Target (mean)
Tgt Median
Tgt Low
Tgt High
# Analysts
Recom None
Prev Close $0.47
Price $0.50
Change 5.57%
About

Silo Pharma Inc. operates as a developmental stage biopharmaceutical company. The company is developing therapeutics that address underserved conditions, including post-traumatic stress disorder (PTSD), stress-induced anxiety disorders, fibromyalgia, and central nervous system (CNS) diseases. It focuses on developing traditional therapies and psychedelic treatments in formulations. The company's lead program, SPC-15, is an intranasal treatment targeting PTSD and stress-induced anxiety disorders. It is also developing SP-26, a time-release ketamine-loaded implant for fibromyalgia and chronic pain relief. In addition, the company's two preclinical programs comprise SPC-14, an intranasal compound for the treatment of Alzheimer's disease, and SPU-16, a CNS-homing peptide targeting multiple sclerosis (MS). The company's research and development programs are conducted through collaborations with Columbia University, Medspray Pharma BV, and the University of Maryland, Baltimore. The company was formerly known as Uppercut Brands, Inc. and changed its name to Silo Pharma, Inc. in September 2020. Silo Pharma, Inc. was incorporated in 2010 and is based in Sarasota, Florida.

Valuation Models

Price estimates from analyst targets and simple models.

1. Analyst consensus Mean price target
2. Current target Latest analyst target
3. DCF / Fair value Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$0.50
Low
High
Mean

Latest analyst rating changes

Date Action Analyst Rating Change Price Target
2023-08-28 init Laidlaw & Co. — → Buy $10
Insider Transactions
Filed Date Insider Relationship Transaction Shares Price Value SEC
2025-12-15 WEISBLUM ERIC Chief Executive Officer 5,000 $0.41 $2,075
2025-11-21 WEISBLUM ERIC Chief Executive Officer 2,000 $0.36 $735
2025-11-19 WEISBLUM ERIC Chief Executive Officer 12,000 $0.40 $4,847
2025-05-27 WEISBLUM ERIC Chief Executive Officer 10,000 $0.43 $4,329
2024-12-13 WEISBLUM ERIC Chief Executive Officer 2,500 $0.84 $2,097
2024-11-22 WEISBLUM ERIC Chief Executive Officer 5,000 $0.90 $4,625
2024-06-12 WEISBLUM ERIC Chief Executive Officer 5,000 $1.08 $5,533
Financials
Statement View
Amounts in millions (2 decimals, no suffix) • EPS per share (2 decimals) • Trend = period evolution • YoY Growth = previous period %
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Total Revenue
0.07
+0.00%
0.07
+0.00%
0.07
+0.00%
0.07
Operating Revenue
0.07
+0.00%
0.07
+0.00%
0.07
+0.00%
0.07
Cost Of Revenue
0.04
+658.74%
0.01
+0.00%
0.01
+0.00%
0.01
Reconciled Cost Of Revenue
0.04
+658.74%
0.01
+0.00%
0.01
+0.00%
0.01
Gross Profit
0.03
-58.04%
0.07
+0.00%
0.07
+0.00%
0.07
Operating Expense
4.31
-9.71%
4.77
+21.68%
3.92
+5.60%
3.71
Research And Development
2.16
-8.75%
2.37
+180.22%
0.85
-34.31%
1.29
Selling General And Administration
2.15
-10.66%
2.40
-21.87%
3.08
+26.75%
2.43
General And Administrative Expense
2.15
-10.66%
2.40
-21.87%
3.08
+26.75%
2.43
Salaries And Wages
0.83
-8.43%
0.91
+4.03%
0.87
+50.89%
0.58
Other Gand A
1.32
-12.00%
1.50
-32.11%
2.21
+27.91%
1.72
Total Expenses
4.35
-8.90%
4.78
+21.64%
3.93
+5.59%
3.72
Operating Income
-4.28
+9.03%
-4.71
-22.05%
-3.86
-5.70%
-3.65
Total Operating Income As Reported
-4.28
+9.03%
-4.71
-22.05%
-3.86
-6.28%
-3.63
EBITDA
-4.18
+4.63%
-4.38
-20.83%
-3.63
+7.14%
-3.91
Normalized EBITDA
-4.08
+6.67%
-4.37
-26.30%
-3.46
+3.30%
-3.58
Reconciled Depreciation
0.01
+84.96%
0.01
0.00
EBIT
-4.19
+4.50%
-4.39
-21.00%
-3.63
+7.14%
-3.91
Total Unusual Items
-0.10
-578.89%
-0.02
+90.97%
-0.17
+48.77%
-0.33
Total Unusual Items Excluding Goodwill
-0.10
-578.89%
-0.02
+90.97%
-0.17
+48.77%
-0.33
Special Income Charges
-0.04
0.00
+100.00%
-0.17
-930.17%
0.02
Other Special Charges
0.17
Impairment Of Capital Assets
0.04
0.00
Write Off
0.00
+100.00%
-0.02
Net Income
-4.23
+3.76%
-4.39
-18.70%
-3.70
+5.32%
-3.91
Pretax Income
-4.23
+3.76%
-4.39
-20.98%
-3.63
+7.07%
-3.91
Net Non Operating Interest Income Expense
0.16
-52.26%
0.33
-16.66%
0.39
+458.88%
0.07
Interest Expense Non Operating
0.04
+633.71%
0.01
+4.42%
0.00
+121.42%
0.00
Net Interest Income
0.16
-52.26%
0.33
-16.66%
0.39
+458.88%
0.07
Interest Expense
0.04
+633.71%
0.01
+4.42%
0.00
+121.42%
0.00
Interest Income Non Operating
0.19
-41.80%
0.33
-16.40%
0.40
+448.66%
0.07
Interest Income
0.19
-41.80%
0.33
-16.40%
0.40
+448.66%
0.07
Other Income Expense
-0.10
-578.89%
-0.02
+90.97%
-0.17
+48.77%
-0.33
Gain On Sale Of Security
-0.06
-317.44%
-0.02
-389.64%
-0.00
+99.11%
-0.35
Tax Provision
0.00
0.00
0.00
0.00
Tax Rate For Calcs
0.00
0.00
0.00
0.00
Tax Effect Of Unusual Items
0.00
0.00
0.00
0.00
Net Income Including Noncontrolling Interests
-4.23
+3.76%
-4.39
-18.70%
-3.70
+5.32%
-3.91
Net Income From Continuing Operation Net Minority Interest
-4.23
+3.76%
-4.39
-20.98%
-3.63
+7.07%
-3.91
Net Income From Continuing And Discontinued Operation
-4.23
+3.76%
-4.39
-18.70%
-3.70
+5.32%
-3.91
Net Income Continuous Operations
-4.23
+3.76%
-4.39
-20.98%
-3.63
+7.07%
-3.91
Net Income Discontinuous Operations
0.00
+100.00%
-0.07
-5884.52%
-0.00
Normalized Income
-4.12
+5.79%
-4.38
-26.45%
-3.46
+3.22%
-3.58
Net Income Common Stockholders
-4.23
+3.76%
-4.39
-18.70%
-3.70
+5.32%
-3.91
Otherunder Preferred Stock Dividend
0.00
Diluted EPS
-1.19
+0.83%
-1.20
+29.82%
-1.71
Basic EPS
-1.19
+0.83%
-1.20
+29.82%
-1.71
Basic Average Shares
3.68
+19.50%
3.08
+34.83%
2.28
Diluted Average Shares
3.68
+19.50%
3.08
+34.83%
2.28
Diluted NI Availto Com Stockholders
-4.23
+3.76%
-4.39
-18.70%
-3.70
+5.32%
-3.91
Insurance And Claims
0.09
-29.30%
0.13
Line Item Trend 2024-12-31 2023-12-31
Total Assets
7.41
-4.32%
7.75
Current Assets
7.11
-7.42%
7.68
Cash Cash Equivalents And Short Term Investments
7.08
-7.63%
7.67
Cash And Cash Equivalents
3.91
+10.82%
3.52
Other Short Term Investments
3.17
-23.33%
4.14
Receivables
0.00
Accrued Interest Receivable
Prepaid Assets
Assets Held For Sale Current
Other Current Assets
0.03
+93.84%
0.02
Total Non Current Assets
0.30
+362.21%
0.06
Goodwill And Other Intangible Assets
0.24
0.00
Other Intangible Assets
0.24
Non Current Prepaid Assets
Other Non Current Assets
0.06
-8.98%
0.06
Total Liabilities Net Minority Interest
2.38
+51.51%
1.57
Current Liabilities
1.66
+113.51%
0.78
Payables And Accrued Expenses
1.58
+125.15%
0.70
Payables
Accounts Payable
Current Deferred Liabilities
0.07
+0.00%
0.07
Current Deferred Revenue
0.07
+0.00%
0.07
Total Non Current Liabilities Net Minority Interest
0.72
-9.08%
0.79
Non Current Deferred Liabilities
0.72
-9.08%
0.79
Non Current Deferred Revenue
0.72
-9.08%
0.79
Stockholders Equity
5.03
-18.50%
6.18
Common Stock Equity
5.03
-18.50%
6.18
Capital Stock
0.00
+42.09%
0.00
Common Stock
0.00
+42.09%
0.00
Preferred Stock
0.00
Share Issued
4.48
+41.95%
3.16
Ordinary Shares Number
4.48
+54.30%
2.91
Treasury Shares Number
0.00
-100.00%
0.25
Additional Paid In Capital
20.30
+15.81%
17.53
Retained Earnings
-15.26
-40.41%
-10.87
Gains Losses Not Affecting Retained Earnings
0.00
+138.85%
-0.01
Treasury Stock
0.00
-100.00%
0.47
Other Equity Adjustments
0.00
+138.85%
-0.01
Total Equity Gross Minority Interest
5.03
-18.50%
6.18
Total Capitalization
5.03
-18.50%
6.18
Working Capital
5.46
-21.00%
6.91
Invested Capital
5.03
-18.50%
6.18
Net Tangible Assets
4.79
-22.40%
6.18
Tangible Book Value
4.79
-22.40%
6.18
Non Current Note Receivables
Notes Receivable
0.00
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Operating Cash Flow
-4.66
-21.58%
-3.83
-18.90%
-3.22
+7.81%
-3.50
Cash Flow From Continuing Operating Activities
-4.66
-21.58%
-3.83
-18.90%
-3.22
+7.81%
-3.50
Cash From Discontinued Operating Activities
0.00
Net Income From Continuing Operations
-4.23
+3.76%
-4.39
-18.70%
-3.70
+5.32%
-3.91
Depreciation Amortization Depletion
0.01
+84.96%
0.01
0.00
Amortization Cash Flow
0.01
+84.96%
0.01
0.00
Depreciation And Amortization
0.01
+84.96%
0.01
0.00
Amortization Of Intangibles
0.01
+84.96%
0.01
0.00
Other Non Cash Items
0.52
0.09
+205.06%
-0.09
Stock Based Compensation
0.12
0.00
-100.00%
0.01
-90.95%
0.16
Provisionand Write Offof Assets
0.07
0.00
Asset Impairment Charge
0.04
0.00
0.00
+100.00%
-0.02
Operating Gains Losses
-0.00
-481.56%
0.00
0.10
Gain Loss On Investment Securities
-0.00
-481.56%
0.00
0.10
Unrealized Gain Loss On Investment Securities
0.07
0.00
-100.00%
0.00
-99.06%
0.33
Change In Working Capital
-1.18
-314.58%
0.55
+84.36%
0.30
+497.51%
-0.08
Change In Receivables
0.00
+100.00%
-0.00
+25.21%
-0.00
Change In Prepaid Assets
-0.12
-1194.75%
-0.01
-125.63%
0.04
-35.49%
0.06
Change In Payables And Accrued Expense
-0.99
-256.94%
0.63
+86.58%
0.34
+731.54%
-0.05
Change In Payable
0.34
+731.54%
-0.05
Change In Account Payable
0.34
+731.54%
-0.05
Change In Other Working Capital
-0.07
+0.00%
-0.07
+0.00%
-0.07
+0.00%
-0.07
Investing Cash Flow
0.64
-33.86%
0.97
+123.48%
-4.15
-4882.90%
0.09
Cash Flow From Continuing Investing Activities
0.64
-33.86%
0.97
+123.48%
-4.15
-4882.90%
0.09
Capital Expenditure
-0.57
Net Investment Purchase And Sale
1.22
+25.18%
0.97
+123.48%
-4.15
-6316.90%
0.07
Purchase Of Investment
-0.10
+44.91%
-0.18
+95.77%
-4.15
Sale Of Investment
1.32
+14.47%
1.15
0.00
-100.00%
0.07
Net Intangibles Purchase And Sale
-0.57
0.00
Purchase Of Intangibles
-0.57
0.00
Net Other Investing Changes
0.02
Financing Cash Flow
4.86
+49.93%
3.24
+788.07%
-0.47
-109.54%
4.94
Cash Flow From Continuing Financing Activities
4.86
+49.93%
3.24
+788.07%
-0.47
-109.54%
4.94
Net Issuance Payments Of Debt
Issuance Of Debt
Repayment Of Debt
Long Term Debt Issuance
Long Term Debt Payments
Net Long Term Debt Issuance
Net Common Stock Issuance
3.73
+14.92%
3.24
+788.07%
-0.47
-109.54%
4.94
Common Stock Payments
0.00
+100.00%
-0.17
+63.26%
-0.47
0.00
Repurchase Of Capital Stock
0.00
+100.00%
-0.17
+63.26%
-0.47
0.00
Proceeds From Stock Option Exercised
1.13
+37832666.67%
0.00
0.00
Changes In Cash
0.84
+120.95%
0.38
+104.86%
-7.84
-612.59%
1.53
Beginning Cash Position
3.91
+10.82%
3.52
-69.00%
11.37
+15.55%
9.84
End Cash Position
4.75
+21.58%
3.91
+10.82%
3.52
-69.00%
11.37
Free Cash Flow
-5.24
-36.58%
-3.83
-18.90%
-3.22
+7.81%
-3.50
Interest Paid Supplemental Data
0.04
+633.71%
0.01
+4.42%
0.00
+121.42%
0.00
Income Tax Paid Supplemental Data
0.00
0.00
0.00
-100.00%
0.03
Common Stock Issuance
3.73
+9.09%
3.41
0.00
-100.00%
4.94
Issuance Of Capital Stock
3.73
+9.09%
3.41
0.00
-100.00%
4.94
Net Preferred Stock Issuance
0.00
Preferred Stock Issuance
0.00
SEC Filings

Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.

Trades
Date User Broker Pattern Type Position Size Entry Price Trade P&L Status
Posts
Published Title Author Category